Certara, Inc. (NASDAQ:CERT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Certara, Inc. (NASDAQ:CERT) has received an average rating of “Moderate Buy” from the eight brokerages that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $15.67.

A number of analysts have weighed in on the stock. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research note on Tuesday, May 6th. TD Cowen assumed coverage on Certara in a report on Thursday, February 27th. They set a “buy” rating and a $16.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Barclays upgraded Certara from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Finally, William Blair reissued a “market perform” rating on shares of Certara in a research note on Thursday, February 27th.

Certara Price Performance

Shares of CERT stock opened at $11.76 on Friday. The business has a fifty day simple moving average of $12.02 and a 200 day simple moving average of $11.83. The company has a market cap of $1.91 billion, a P/E ratio of -58.80, a P/E/G ratio of 9.29 and a beta of 1.44. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara has a twelve month low of $8.64 and a twelve month high of $17.22.

Certara (NASDAQ:CERT) last posted its earnings results on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.04. The firm had revenue of $106.00 million during the quarter, compared to analysts’ expectations of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. On average, sell-side analysts forecast that Certara will post 0.28 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ArrowMark Colorado Holdings LLC raised its stake in Certara by 164.2% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company’s stock worth $66,171,000 after buying an additional 3,861,674 shares during the period. Ameriprise Financial Inc. raised its position in shares of Certara by 864.0% in the fourth quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company’s stock valued at $40,253,000 after purchasing an additional 3,387,590 shares during the period. Mackenzie Financial Corp purchased a new position in shares of Certara in the fourth quarter valued at $17,852,000. Brown Brothers Harriman & Co. grew its stake in Certara by 63.8% during the fourth quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company’s stock valued at $40,668,000 after acquiring an additional 1,487,998 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Certara by 169.0% during the fourth quarter. Bank of New York Mellon Corp now owns 1,995,071 shares of the company’s stock valued at $21,248,000 after buying an additional 1,253,385 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.